Abstract:A211 Cervical cancer caused by the high-risk strains of Human papillomavirus (HPV) and levels of the tumor suppressor protein p53 were found to be unusually low due to the presence of E6 and E7 proteins encoded by the oncogenic HPV. Expression of Human papillomavirus E6 and E7 is necessary to maintain the transformed state of cervical cancer cells. The E6 promoted degradation of p53 involves the ubiquitin-proteasome pathway and represents a major mechanism, by which virus transforms the host cells. The ability of E6 to target multiple cellular tumor suppressor proteins, notably p53 and several PDZ family numbers enforces the necessity for the development of potential therapeutic targets for the rapid proteolytic degradation. Initial studies with only licensed proteasome inhibitor, Bortezomib (Velcade/PS-341) indicated a therapeutic index in HPV transformed as compared to HPV negative cervical cancer lines, and immortalized or primary keratinocytes, suggesting the promise of this approach. Indeed, Bortezomib (1mg/kg, twice weekly) significantly retarded the growth of the HPV18-transformed HeLa cell xenograft. However, although Bortezomib restored the expression of wild type p53 in several cervical cancer cell lines, it had no effect upon expression of several important PDZ tumor suppressors, hDlg, hScribble, hMAGI family. Therefore, we began an effort to develop potent second generation proteasome inhibitors that prevent E6-mediated degradation of more of its target cellular proteins based on our previously published compound 3,5-bis-(4-boronic acid-benzylidene)-1-methyl-piperidin-4-one(AM114). Through a series of modifications of this family, including attachment of various peptides to target different proteolytic activities of the proteasome, we have explored the chemical space surrounding this compound to develop comprehensive structure activity relationships. The new lead compound, AMV-146 exhibits a Ki of ~2µM for in vitro killing of HeLa and CaSki cells (HPV18 and HPV16 transformed cells respectively). AMV-146 restored wild type p53 expression in HeLa, and HPV16-transformed SiHa and CaSki cells, but had no effect upon p53 expression in HPV-negative HT3 cells and the spontaneously immortalized keratinocyte line HaCaT. Two related compounds, KI-VI-58 and KI-VI-55 exhibit Ki of ~2µM and 2.5µM against both HeLa and CaSki cells.

Triphenyl Tin Benzimidazolethiol, a Novel Antitumor Agent, Induces Mitochondrial-Mediated Apoptosis in Human Cervical Cancer Cells Via Suppression of HPV-18 Encoded E6

p53-dependent apoptotic mechanism of a new designer bimetallic compound tri-phenyl tin benzimidazolethiol copper chloride (TPT-CuCl2): in vivo studies in Wistar rats as well as in vitro studies in human cervical cancer cells.

A novel dithiocarbamate derivative induces cell apoptosis through p53-dependent intrinsic pathway and suppresses the expression of the E6 oncogene of human papillomavirus 18 in HeLa cells

A Novel Biphenyl Urea Compound, TPD7, Stimulates Apoptosis Through Modulating Fas Signaling and Bcl-2 Family Proteins in Cervical Cancer.

Small Molecule CDS-3078 Induces G2/M Phase Arrest and Mitochondria-Mediated Apoptosis in HeLa Cells

Discovery of 2-(2-aminobenzo[d]thiazol-6-yl) Benzo[d]oxazol-5-amine Derivatives That Regulated HPV Relevant Cellular Pathway and Prevented Cervical Cancer from Abnormal Proliferation.

Antihepatocellular Carcinoma Potential of Tetramethylpyrazine Induces Cell Cycle Modulation and Mitochondrial-Dependent Apoptosis

Candidate Proteasome Inhibitors That Prevent E6 Mediated P53 Degradation and Selectively Kill Hpv Plus Cervical Cancer Cells

P-Glycoprotein-Independent Apoptosis Induction By A Novel Synthetic Compound, Mmpt [5-[(4-Methylphenyl)Methylene]-2-(Phenylamino)-4 (5h)-Thiazolone]

Apoptotic effect of novel pyrazolone-based derivative [Cu(PMPP-SAL)(EtOH)] on HeLa cells and its mechanism

Targeted Disruption of E6/p53 Binding Exerts Broad Activity and Synergism with Paclitaxel and Topotecan against HPV-Transformed Cancer Cells

Γ-Tocotrienol Inhibits Proliferation and Induces Apoptosis Via the Mitochondrial Pathway in Human Cervical Cancer HeLa Cells

Apoptosis Induced by an Antagonist Peptide Against HPV16 E7 in Vitro and in Vivo Via Restoration of P53.

Hpv E6 Down-Regulation and Apoptosis Induction of Human Cervical Cancer Cells by A Novel Lipid-Soluble Extract (pe) from Pinellia Pedatisecta Schott in Vitro

Combination Treatment with Dihydrotanshinone I and Irradiation Enhances Apoptotic Effects in Human Cervical Cancer by HPV E6 Down-Regulation and Caspases Activation.

The Novel Benzothiazole Derivative PB11 Induces Apoptosis via the PI3K/AKT Signaling Pathway in Human Cancer Cell Lines

Discovery of 2,4-diphenyl-substituted thiazole derivatives as PRMT1 inhibitors and investigation of their anti-cervical cancer effects

Induction of G2/M Phase Arrest and Apoptosis by Potent Antitumor APCA in Human Cervix Carcinoma Cells

Ethyl 2- [N-M-chlorobenzyl- (2'-Methyl)] Anilino-4-oxo-4,5-dihydrofuran-3-carboxylate (JOT01006) Induces Apoptosis in Human Cervical Cancer HeLa Cells.

Hesperidin Induces Mitochondria Mediated Intrinsic Apoptosis in HPV-positive Cervical Cancer Cells via Regulation of E6/p53 Expression

10H-3,6-Diazaphenothiazine induces G2/M phase cell cycle arrest and caspase-dependent apoptosis and inhibits cell invasion of A2780 ovarian carcinoma cells through the regulation of NF-κB and (BIRC6-XIAP) complexes